News | May 05, 2026
NIFTY Pharma remains resilient amid mixed market sentiment
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Pharma and healthcare stocks stay in focus as investors track earnings, USFDA approvals, hospital growth, and global market pressures
Keeps Halo Pharma to drive independent growth
Acquisition to expand the company's women’s health and biosimilars footprint, positioning it among top 25 drugmakers globally
Growth was broad-based across segments
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The event showcased latest breakthroughs in minimally invasive surgery, organ-preservation strategies, and targeted therapies
The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21
Chronic GVHD is a serious and potentially life-threatening condition, imposing profound physical and emotional burdens on a substantial proportion of patients following allogeneic stem cell transplantation
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
Subscribe To Our Newsletter & Stay Updated
